Panacea Biotec shares rise over 9% after completing Phase III enrollment for its dengue vaccine DengiALL, a potential first indigenous single-shot dengue vaccine in India.
Granules India announced today that U.S. based company, Granules Pharmaceuticals, Inc., has gotten probable designation of the U.S. Food and Drug Administration (FDA) on its generic amphetamine prolonged discharge pills that treat attention...
Eli Lilly buys Ventyx as it builds its infiltration in inflammation-related diseases. The Indianapolis-based pharma giant reported today that it has initiated into a final deal to acquire Ventyx Biosciences. Ventyx Biosciences is a San Diego...
Dr. Lal PathLabs Limited today announced the launch of the Sovaaka Diagnostic Experience Centre in Gurugram, marking a major step in the evolution of preventive healthcare in India. The launch was graced by Haryana Chief Minister Nayab Singh...
Abbott launches Libre Assist at CES 2026, a smart Libre app feature using AI and CGM data to guide meal choices and predict glucose impact for people with diabetes.
Biocon Ltd announced Tuesday that its unit Biocon Biologics oncology biosimilars will expand with three new cancer therapies aimed at strengthening its presence in the global oncology market. With a regulatory filing, the company announced that...
Lupin Ltd announced today that its subsidiary, Lupin Manufacturing Solutions has entered into a longterm agreement with PolyPeptide Group AG. The joint venture will strengthen the global peptide-based active pharmaceutical ingredients supply...
Sun Pharmaceutical Industries has secured a major win after the Ahmedabad bench of the Customs, Excise and Service Tax Appellate Tribunal granted Sun Pharma CESTAT relief by setting aside a Rs 39 crore excise duty demand raised by tax authorities...
Eli Lilly has entered into a huge collaboration with Nimbus Therapeutics to develop a new obesity pill. This action assists Lilly in its quest to get out of injectable weight-loss drugs. The transaction, which was announced today, is aimed at...
Dr Reddy’s launches Hevaxin, India’s only DCGI-approved hepatitis E vaccine, offering long-term immunity and supporting national efforts to reduce liver disease burden.